Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et al

Affiliations

• ¹ Departament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, Catalonia, Spain. jbonaventura@ub.edu.
• ² Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. jbonaventura@ub.edu.
• ³ Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
• ⁴ Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, MD, USA.
• ⁵ Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, USA.
• ⁶ Neurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
• ⁷ Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
• ⁸ Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. mike.michaelides@nih.gov.
• ⁹ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mike.michaelides@nih.gov.